Table 2. Patients’ Clinical Status at Randomization and Medications Receiveda.
| All patients | Convalescent plasma group (n = 52) | Control group (n = 51) |
|---|---|---|
| Time between symptom onset and randomization, median (IQR), d | 27 (22-39) [n = 49] | 30 (19-38) [n = 48] |
| ≤14 d, No. (%) | 3/49 (6.1) | 5/48 (10.4) |
| >14 d, No. (%) | 46/49 (93.9) | 43/48 (89.6) |
| Interval between symptom onset and admission, median (IQR), d | 12 (5-20) [n = 49] |
10 (6-16) [n = 48] |
| 6-Point scale at study day 1, No. (%) | ||
| 2- Hospitalization, no supplemental oxygen | 1/51 (2.0) | 1/50 (2.0) |
| 3- Hospitalization, requiring supplemental oxygen (not high-flow or noninvasive ventilation) | 15/51 (29.4) | 15/50 (30.0) |
| 4- Hospitalization, requiring noninvasive ventilation and/or high-flow supplemental oxygen | 21/51 (41.2) | 23/50 (46.0) |
| 5- Hospitalization, requiring extracorporeal membrane oxygenation and/or invasive mechanical ventilation | 14/51 (27.5) | 11/50 (22.0) |
| Medications used after randomization | ||
| Antiviral | 41/46 (89.1) | 44/49 (89.8) |
| Antibacterial | 38/46 (82.6) | 39/49 (79.6) |
| Chinese herbal medicine | 26/46 (56.5) | 30/49 (61.2) |
| Steroids | 21/46 (45.7) | 16/49 (32.7) |
| Antifungal | 15/46 (32.6) | 13/49 (26.5) |
| Human immunoglobulin | 13/46 (28.3) | 11/49 (22.5) |
| Interferon | 12/46 (26.1) | 7/49 (14.3) |
a
The values shown were based on total number of patients who contributed values. Details of medications used were provided in eTable 7 in Supplement 3.